EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
Abstract
Material & Methods: This randomized controlled trial was conducted at Medical Unit A, Khyber Teaching Hospital, Peshawar, Pakistan. Duration of the study was six months in which a total of 122 patients were observed with 61 patients in each group. Consecutive, non-probability sampling technique was used for sample collection.
Results: Our study shows that mean age of the patients in Group A (rifaximin plus lactulose) was 50±2.31 years, while mean age of the patients in Group B (lactulose alone) was 52±2.78 years. In Group A 48% patients were males and 52% patients females while in Group B 45% patients were males and 55% females. Regarding the efficacy, rifaximin plus lactulose was effective in 45(74%) patients while lactulose alone was effective in 32(53%) patients with hepatic encephalopathy.
Conclusion: Lactulose plus rifaximin orally is more effective than lactulose alone in the treatment of acute hepatic encephalopathy.
Full Text:
PDFRefbacks
- There are currently no refbacks.
Copyright (c) 2020 Hafsa Habib, Dur-e- Nayab, Zafar Hayat, Shahid Jamil, Habibullah Khan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Gomal Medical College, Daraban Road, Dera Ismail Khan, Pakistan
ISSN: 1819-7973, e-ISSN: 1997-2067
Website: https://www.gmcdikhan.edu.pk
Phone: +92-966-747373